Climb Bio Raises $110M, Budoprutug SC Shows Robust B-Cell Depletion, pMN Fast Track
Climb Bio raised $110 million in a placement, boosting cash to $146.3 million as of March 31, 2026. Budoprutug SC formulation showed robust B-cell depletion matching IV dosing, supporting autoimmune patient studies and ongoing Phase 2 pMN trials with Fast Track designation.
1. First Quarter Financial Results
Climb Bio held $146.3 million in cash, cash equivalents and marketable securities as of March 31, 2026, supporting ongoing operations and upcoming clinical data milestones.
2. Budoprutug Clinical Progress
Budoprutug’s subcutaneous formulation demonstrated robust B-cell depletion comparable to intravenous dosing in healthy volunteers, prompting a planned multiple-dose autoimmune patient study. The anti-CD19 antibody is enrolling Phase 2 primary membranous nephropathy patients with FDA Fast Track status, while Phase 1b/2a immune thrombocytopenia and global and China Phase 1b SLE trials advance on schedule.
3. CLYM116 Development Updates
CLYM116, an anti-APRIL monoclonal antibody, is in a healthy volunteer Phase 1 trial with initial PK/PD data expected mid-2026, and modeling and safety results will be presented at the European Renal Association Congress in June.
4. Corporate Financing and Outlook
On April 29, 2026, the company completed a $110 million private placement led by healthcare investors, strengthening its balance sheet ahead of anticipated data readouts across multiple programs.